SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense community debate as the stock hits multi-year lows, driven by concerns over its debt-fueled Bitcoin acquisition strategy and the stability of its preferred equity offerings. While some investors view the current price as a structural value opportunity to accumulate shares, a vocal segment of the community warns of ongoing shareholder dilution and potential risks to the company's long-term solvency.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is trending as retail investors rally behind the stock, driven by strong sentiment on social media platforms that frame the company as a prime short-squeeze candidate with solid long-term fundamentals. The community is actively debating whether current volume levels can sustain a parabolic move, with many users encouraging others to hold shares to squeeze short positions while others caution about the risks of a classic pump-and-dump dynamic.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant volatility following its first post-IPO earnings release, which showed strong revenue growth but was accompanied by concerns over shrinking gross margins and upcoming insider share lockup expirations. While the company announced a major multi-year partnership with OpenAI, investors are heavily debating the sustainability of its valuation and the impact of potential insider selling pressure.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant downward pressure and intense community frustration as the stock faces a sharp correction, with investors debating whether the selloff is an algorithmic overreaction or a fundamental response to concerns over debt and capital expenditure. Despite strong backlog figures and long-term bullish sentiment from some, many participants are calling for management changes and expressing disbelief at the persistent disconnect between the company's enterprise cloud growth and its recent price performance.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is facing intense downward pressure and negative investor sentiment as shareholders express frustration over ongoing leadership challenges and disappointing oncology trial results. While the community remains divided, many are actively debating whether the stock's high dividend yield makes it a defensive value play or if deep-seated operational struggles warrant further bearish outlooks.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing heightened activity as traders weigh new investments in autonomous vehicle technology, including a significant stake in robotaxi developer Nuro, against broader market volatility impacting growth stocks. The community remains divided, with many highlighting the stock's strong fundamentals and potential World Cup demand tailwinds while others express frustration over persistent technical weakness and skepticism toward high autonomous vehicle operational costs.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing high volatility as investors weigh strong fundamental growth and a recent analyst upgrade against aggressive short selling and broader software sector pressure. The community is actively debating the impact of AI-driven design tools on the company's long-term moats, while bulls look toward the upcoming Config conference as a potential catalyst for a reversal.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is gaining momentum as investors track significant clinical progress, specifically the commencement of dosing in a Phase 1/2a trial for its hair regrowth antibody, alongside growing anticipation for potential large-pharma partnerships. The community remains focused on the company's AI-driven drug discovery platform, with active discussions weighing the high-risk, high-reward profile of its internal pipeline against institutional support.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is experiencing intense community focus as market participants monitor imminent catalysts surrounding the GTA VI launch, specifically the highly anticipated opening of pre-orders and potential trailer releases. While volatility remains elevated, investors are debating whether the current price reflects long-term revenue potential or if the stock is susceptible to 'sell-the-news' pressure following recent analyst upgrades and pre-order momentum.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is facing intense retail scrutiny as the stock trends near all-time lows, with investors expressing significant frustration over ongoing share dilution and a widening disconnect between the company's market performance and its underlying Ethereum holdings. Community discourse is dominated by accusations of management misleading shareholders and skepticism regarding the company's long-term value, as traders debate whether current price levels represent a capitulation bottom or a terminal decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review

Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.

Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time

Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.read more...

OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision

Equity

The agency will now decide whether to approve the drug by July 29, 2026.

OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal  

A decision on the resubmitted application is expected within 60 days of the FDA’s receipt of it, the company said.


OTLK Stock Rocket Nearly 140%: Lytenava Dispute Resolution With FDA Pushes Stock On Track For Best Week On Record

Outlook Therapeutics wins appeal following formal dispute resolution process for LYTENAVA.

Why RDW, TE, OTLK Stocks Posted Double-Digit Gains On Tuesday

Redwire, T1 Energy, and Outlook Therapeutics shares soared due to broad sectoral optimism, strong institutional backing, and positive company developments, respectively. 

Traders Rush into AI, Biotech, and Emerging Tech

Momentum traders are aggressively rotating into AI infrastructure, biotech catalysts, blockchain exposure, and emerging technology plays as speculative appetite continues heating up across small-cap and high-growth sectors. $KBLB, $OTLK, $PHGE, $UZX, $QTEK $ARTL, $VCIG, $YMAT, $NCRA

Outlook Therapeutics Stock Climbs 38% After Winning FDA Appeal For NAMD Therapy

(RTTNews) - Shares of Outlook Therapeutics, Inc. (OTLK) are climbing about 38 percent in Tuesday morning trading after the company announced that the U.S. FDA has granted its appeal following completion of the Formal Dispute Resolution process for ONS-5010/LYTENAVA, its investiga...

OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally?

The U.S. Food and Drug Administration granted Outlook Therapeutics its appeal following a formal dispute resolution process related to its eye disease drug Lytenava.

Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Outlook Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are closely tracking the stock's climb, with significant hype around breaking the $2 threshold and reaching NASDAQ compliance.

Anticipation is mounting for the upcoming July 29th FDA approval decision, which traders view as the major engine for potential upside.

Bullish investors are calling out short sellers, viewing recent volatility as a 'shakeout' to clear weak hands before a potential squeeze.

Traders are actively sharing their accumulation strategy, emphasizing that buying during pullbacks is key to long-term gains.

Feed

News

Sentiment

Earnings

Fundamentals

Info

OTLKOutlook Therapeutics Inc

Fundamentals

Latest OTLK News